Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of LY2969822 in Healthy Subjects
NCT02018887Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2013
- Primary completion
- Feb 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LY2969822 in pain (6 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants With One or More Serious Adverse Events (SAEs) Considered by the Investigator to be Related to Study Drug Administration. Started Dec 2013; status: completed.
02
Drugs
LY2969822
03
Conditions
pain
Beyond the preview
Go deeper on NCT02018887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02018887.